A novel human epidermal growth factor receptor-3 targeting antibody-drug conjugate for treatment of cancer


An Italian SME specialized in drug discovery has developed and patented a novel human epidermal growth factor receptor-3 (HER-3) targeting antibody-drug conjugate (ADC) for treating cancer. This molecule has shown potent therapeutic efficacy combined with a good safety profile.
The company is looking for pharmaceutical companies or investors for financial or license agreement to further develop the product in clinical trials. A research cooperation agreement is also foreseen.
ACTIS Cooperación Tecnológica
Enlace: A novel human epidermal growth factor receptor-3 targeting antibody-drug conjugate for treatment of cancer

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

ACEPTAR
Aviso de cookies